CamsPaMS Organising Committee Members

---

ThermoFisher Scientific

I have a degree in Chemistry from the University of York and a PhD in analytical chemistry from the University of Reading. Following a post-doc in mass spectrometry in the Chemistry department at Oxford, and working as an application scientist at Waters, I worked in and ran Proteomics Core Facilities in the UK and Germany, including the EMBL in Heidelberg, the Leibniz Institute on Aging in Jena, The Francis Crick Institute in London and CRUK Cambridge. After many years as an experienced Thermo customer, I joined the company in 2023 as a Technical Sales Specialist, supporting the whole of the UK/Ireland, Benelux and Nordic regions, in all things proteomics. When I’m not talking about proteomics and mass spectrometry I enjoy ceroc dancing, tennis, scuba diving, travelling, and spending time with my cats, who like to join in on Teams meetings whenever I work from home.

Cambridge Institute for Medical Research

I co-manage the Cambridge Institute for Medical Research Proteomics Facility helping to provide a wide range of proteomics options for internal, external and commercial users around the UK and beyond. I typically focus on proteomics method development, particularly for studying protein ubiquitylation, misfolding, and aggregation in aging. Most recently, this has included devising a pipeline for the LC-MS characterisation of poly-ubiquitylated proteins (termed Ubi-SCAPE) and a simplified proteomics clean-up approach (SP4). I did my PhD and a postdoc in cancer proteomics at Southampton University and a postdoc in biomarker discovery at UCL. I am also a serial discussion group founder (see also LPDG).

Bicycle Therapeutics

I am a Principal Scientist and leader of the Analytics Team at Bicycle Therapeutics. The team specialises in mass spectrometry and my primary role is to ensure the company is making maximum use of all the various flavours of mass spectrometry and to generate and test reagents used in the downstream discovery projects.

Mass spec, in all its various guises, is an amazingly powerful tool that can answer many questions from all stages of pharmaceutical discovery and development, and in many other industries.

I am a founder member of CamsPaMS and my vision is to grow the meeting to enable the mass spec community in Cambridge, and further afield, to continue to flourish, and to make the technology accessible to as many scientists as possible.

Cambridge University  

I began my career at the Horse Racing Forensic laboratory in Newmarket in 2000, developing methods to detect steroid abuse in horses and pro-steroid contaminants in sports supplements. I then performed a part time PhD with Colin Creaser at the University of Loughborough (2005-2010) developing plasma proteomics methods to detect growth hormone abuse in athletes and then transferred to the Bioanalytical Group to develop GLP and GCP validated methods for measuring peptide and protein drugs for pharmaceutical companies. In 2016 I moved to the University of Cambridge to set up a Peptidomics facility and has since developed methods to measure endogenous peptides and proteins in plasma, tissue homogenates, primary culture supernatants, organoids and sorted cells to support research performed by the MRC Institute of Metabolic Science.

EMBL-EBI

  I am currently a senior scientific database curator and project liaison at UniProt, based at EMBL-EBI in Hinxton, Cambridge. I am passionate about scientific communication and work with both the curation and website development teams at UniProt to drive user-centric improvements and data integration in response to community feedback. My research background is in wet-lab proteomics investigation of aberrant signalling pathways in cancer and I now act as UniProt’s proteomics subject matter expert and focus my efforts on integration of large-scale PTM-enriched proteomics data and curation of mammalian proteins involved in cell adhesion, disease mechanisms and osteogenesis.

CRUK Cambridge

I am a Scientific Associate at the Proteomics Core Facility within the Cancer Research UK Cambridge Institute. Before this role, I completed a PhD at the University of Birmingham, specialising in ageing muscle biology and ubiquitylation where I developed and optimised sample preparation techniques for proteomics analysis. In my current role, I work with a team of scientists to provide a wide range of proteomic analyses for internal and external research groups. I am passionate about undertaking method development projects, especially in the field of PTMs, to improve the facility's expertise and expand our capabilities for users.

Resolian

I am a Principal Scientist at Resolian. My role includes leading and overseeing the development of LC-MS methods for the quantitation of a wide range of pharmaceuticals, biopharmaceuticals and biomarkers from complex biological matrices. I specialise in the analysis of biopharmaceuticals and biomarkers using a bottom-up approach and in the application of Hybrid/Immunoprecipitation-LC-MS and High-Resolution Mass Spectrometry techniques. 

Before joining Resolian, I completed my PhD under the supervision of Professor Perdita Barran at the University of Manchester. My PhD focussed on investigating the early-stage aggregates of amyloidogenic proteins and peptides using a range of techniques including native mass spectrometry, various gas phase fragmentation approaches, Hydrogen Deuterium Exchange Mass Spectrometry and Ion Mobility-Mass Spectrometry.

AstraZeneca

I am an Associate Principal Scientist in the Mechanistic Biology and Profiling Department at AstraZeneca. I am responsible for designing mass spectrometry assays for early-stage drug discovery projects. Before this, I was a postdoc at the Beatson Institute in Glasgow studying biomarkers of early-stage pancreatic cancer and the role of alcohol abuse on hepatocellular carcinoma development. I also conducted my PhD and postdoc at the Karolinska Institute under Prof. Sonia Laín and Prof. Sir David Lane in p53 drug discovery employing phenotypic screens for p53 reactivating agents underpinned by proteomics and native MS of a novel target - DHODH. I started my academic career with Prof. Malcolm Tingle where I did my MSc in pharmacology and toxicology at the University of Auckland looking at drug metabolism by endogenous microbiota utilising mass spectrometry to understand chemotherapeutic gut toxicity.